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OBJECTIVES: To describe the clinical and economic burden of COPD patients with 
IA (COPD + IA), antifungal treatment patterns, and the impact of index antifungal 
selection on total costs, length of stay (LOS) and mortality. METHODS: This retro-
spective cohort study used 2005–2008 data from the Premier Perspective database of 
>500 U.S. hospitals. COPD + IA patients were identiﬁed based on ICD-9 codes for 
COPD + Aspergillosis + Pneumonia. Patients were excluded if ICD-9 codes were 
present for malignancies, HIV, or conditions that increase risk for IA aside from 
COPD. Demographics, hospital characteristics, and antifungal treatment patterns 
were examined. Excess resource utilization was analyzed by matching cases (COPD + 
IA) and controls (COPD patients without Aspergillosis) on demographic and clinical 
variables. Regression analyses were conducted on the impact of the index antifungal 
on total costs, LOS and mortality controlling for patient demographics, hospital 
characteristics, co-morbidities, and disease severity. RESULTS: We identiﬁed 475 
COPD + IA patients (mean age 69 years, 50% male, 76% Caucasian). COPD + IA 
cases had signiﬁcantly higher costs ($48,163 vs $30,210), LOS (23.2 vs 13.6 days), 
ICU stay (13.8 vs 7.2 days), and mortality (29% vs 23%) compared to COPD controls 
(all p < 0.01). Antifungal therapy was initiated on day 6, with length of therapy of 
15 days, and one-third of patients were in ICU when initiated. Most commonly used 
antifungals were voriconazole, ﬂuconazole, and caspofungin. After controlling for 
covariates, patients receiving ﬂuconazole as the index antifungal had greater mortality 
(40% vs 22%, p = 0.023), 4 additional hospital days (p = 0.007), and 24% greater 
costs (p = 0.003) compared to patients receiving voriconazole ﬁrst-line. Findings were 
consistent in sub-analyses (eg, ICU patients). CONCLUSIONS: COPD + IA patients 
had signiﬁcantly higher mortality, resource utilization, and costs versus controls. 
Treatment with an agent active against Aspergillus increased survival and reduced 
economic burden, thus this potential etiology should be considered when contemplat-
ing antifungal therapy in COPD patients.
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OBJECTIVES: Estimate the incremental impact of HCV on health care costs and 
events using claims data from a large U.S. health insurance provider. METHODS: 1:1 
matched samples of newly diagnosed HCV and non-HCV patients were identiﬁed 
using propensity scoring techniques. Costs and events were measured over the ﬁrst 
post-diagnosis year for HCV patients. Non-HCV patients were assigned an index date 
corresponding to the index date of their matched HCV patient. RESULTS: A total of 
60,806 HCV patients were identiﬁed using 6 years of data based on two or more HCV 
diagnoses or a single diagnosis combined with an HCV-related prescription. Further 
screening for at least one year of eligibility prior to index date and pre-existing HIV, 
hepatitis B, cirrhosis, liver cancer or a liver transplant resulted in an initial HCV 
population of 9191 patients. An additional 410,605 non-HCV patients were identiﬁed 
with similar criteria during their ﬁrst year of eligibility. Both samples were used to 
estimate a parsimonious logistic propensity score model of HCV diagnosis. A total of 
9,129 HCV patients were matched with non-HCV patients [99.3% match rate]. The 
incremental cost of HCV was estimated at +$17,307 over the ﬁrst post-index year. 
HCV doubled the likelihood of hospitalization or a future diagnosis of depression and 
dramatically increased the risk of cirrhosis, liver cancer and liver transplantation were 
increased dramatically by an HCV infection [OR = 62.4, 26.4 and 44.4 respectively]. 
CONCLUSIONS: The incremental cost of HCV in the ﬁrst post-index year is quite 
high due in part to the increased risk of cirrhosis, liver cancer and transplantation. A 
longer term study is needed to investigate economic consequences over time for these 
newly recognized HCV patients.
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THE COST OF TUBERCULOSIS CONTROL IN THE ADULT 
POPULATION OF THE REPUBLIC OF ARMENIA, 2006
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OBJECTIVES: The economic burden of tuberculosis (TB) in Armenia, to our knowl-
edge, has not been assessed. The objective of our study was to estimate total yearly 
direct costs of TB care for adult patients in Armenia, from a societal perspective, for 
2006. METHODS: We used ofﬁcial sources of epidemiological data to estimate the 
total number of prevalent cases of TB within the adult population, including those from 
the civil population and the Armenian penitentiary system. The average direct total 
costs per TB patient were assumed to be similar to the costs reported for the Russian 
Federation. We base this assumption on the similar health care systems, TB policies and 
case management within these two countries. Sensitivity analyses have been conducted 
to deﬁne possible ranges for costs of TB care in Armenia. RESULTS: The incidence and 
prevalence rates of TB in Armenia in 2006 were 48.6 and 176.1 per 100.000 inhabit-
ants, respectively. About 75.9% of all TB cases were smear-positive (BK+); overall 
proportion of children and adolescents was about 8.1%. Assuming that the average 
yearly per-patient costs of managing BK+ and smear-negative (BK-) cases were $359 
and $239, respectively, an overall cost estimate for TB control in the adult population 
of Armenia for 2006 totals to USD 1.41 mill. (range: USD 1.34–1.48 mill.). CONCLU-
SIONS: Despite the uncertainties around current prevalence estimates and cost data per 
TB patient in Armenia, even the lowest possible range of the estimated overall economic 
burden of TB seems to be prohibitively high for a developing country such as Armenia. 
Insufﬁcient ﬁnancial resources available for controlling this disease may contribute to 
the worsening of epidemics. Further studies are warranted to assess the current epide-
miological situation and costs of TB management in Armenia.
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OBJECTIVES: To analyze and compare costs of treatment of complicated infections 
from patients in public and private hospitals METHODS: A retrospective (2008–
2009) medical chart analysis was performed in two hospitals in Sao Paulo City, Brazil: 
Private setting and Public setting. Data from patients over 18 years old with compli-
cated skin/soft tissues infections, complicated abdominal infections and Community 
Acquired Pneumonia (CAP) were analysed according with type and etiologic agent of 
infection, antibiotic use as empiric therapy, bacterial resistance environment and ward 
or ICU treatment and patients. Total treatment costs were evaluated and expressed in 
Brazilian local currency (Reais) RESULTS: A total of 50 medical records randomly 
screened were analyzed, 25 from each hospital. Approximately 34% of each pathology 
and 32% of patients had ICU hospitalization in both settings. The average cost of 
private hospital was R$17,072.08, being 55% due to antibiotics use. Ceftriaxone was 
the most used antibiotic as initial therapy,50% of cases. 56% of patients in private 
hospital had to change antibiotic therapy once at least. In public hospital average cost 
was R$ 2,051.40 and the antibiotics change remained in the same proportion compar-
ing to the private hospital. Mortality rate was different in Private in Public setting 
CONCLUSIONS: The use of appropriate empirical therapy of antibiotic is essential 
and appears as an important cost driver, mainly to the decision makers who under 
these total acknowledgement (scientiﬁc and economic aspects) could have a useful tool 
for supply policy interventions. Furthermore combining clinical and cost allows for 
the best choice of antibiotic use as empirical therapy in these patients
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OBJECTIVES: Acute otitis media (AOM) is extremely common in young children, 
with 75% having at least one episode by one year of age. Streptococcus pneumoniae 
(Sp) and non-typeable Haemophilus inﬂuenzae (NTHi) are the two most commonly 
isolated pathogens in AOM cases. The 7-valent (PCV-7) and 13-valent (PCV-13) 
pneumococcal conjugate vaccines have similar carrier proteins and protect only 
against AOM caused by Sp serotypes contained in the vaccines. The 10-valent pneu-
mococcal vaccine (PHiD-CV) has eight of its ten serotypes conjugated to protein D 
from NTHi and may be regarded as the ﬁrst dual pneumococcal pathogen vaccine 
with a potential to prevent AOM caused by both Sp and NTHi. We estimate the 
clinical and economic impact of these three vaccines on AOM outcomes in Canada. 
METHODS: A steady-state, population-based model with a one-year time horizon 
was developed and calibrated with Canadian epidemiologic and demographic data. 
The health care system perspective was considered assuming 100% vaccination cover-
age, no herd protection and a 3 + 1 vaccination schedule. One-way sensitivity analysis 
was preformed to assess the impact of changes in key model assumptions. RESULTS: 
At price parity, the annual AOM-related cost-savings to the Canadian health care 
system due to the implementation of a PHiD-CV vaccination program is estimated at 
$17.1M and $12.3M compared to PCV-7 and PCV-13 respectively. Compared to 
PCV-7, vaccination with PHiD-CV could prevent an additional 171,162 ambulatory 
visits for AOM, 144,632 antibiotic prescriptions for AOM, and 9,827 hospitalizations 
for myringotomy per year. Compared to PCV-13, PHiD-CV could prevent 123,385 
ambulatory visits for AOM, 104,269 antibiotic prescriptions for AOM, and 7,084 
hospitalizations for myringotomy per year. Sensitivity analyses indicate that efﬁcacy 
against AOM have the biggest impact on model results. CONCLUSIONS: Implemen-
tation of a PHiD-CV vaccination program in Canada is projected to substantially 
reduce AOM burden compared to PCV-7 or PCV-13.
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FOR TREATMENT OF VENTILATOR-ASSOCIATED PNEUMONIA (VAP) 
IN COLOMBIA
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OBJECTIVES: Determine the cost-effectiveness of three carbapenemic anti-infectives 
(imipenem, meropenem and doripenem) for treatment of VAP in Colombia. 
